Lv21
140 积分 2026-08-24 加入
Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series
1个月前
已完结
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy
1个月前
已完结
Chimeric antigen receptor–based cell therapies for neuroimmune disorders: Therapeutic advances and structured standard treatment models
1个月前
已完结
Anti-CD19 CAR T cells for refractory myasthenia gravis
1个月前
已完结
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy
1个月前
已完结
Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease
1个月前
已完结
皖公网安备34019202002308
